Medscape

1 day ago | medscape.com | Priscilla Lynch

Mental health inpatient services in England continue to ignore critical safety recommendations, putting patients and staff at risk, according to a new report. The Health Services Safety Investigations Body (HSSIB) based its findings on multiple investigations into inpatient mental health care between September 2024 and January 2025. The report highlighted persistent systemic failures that have persisted despite previous warnings.

1 day ago | medscape.com | Marc Fröhling

Whether among passengers or crew, seasickness remains one of the most frequent medical issues encountered on board ships. At the 131st Congress of the German Society for Internal Medicine, Andreas H. Leischker, MD, specialist in internal medicine, emergency medicine, aviation medicine, and sports medicine and an experienced ship physician, shared practical insights on the prevention and management of motion sickness at sea. This article is based on Leischker’s lecture delivered during the congress.

1 day ago | medscape.com | Louise Gagnon

Five years after the legalization of cannabis in Canada, cannabis use frequency has risen slightly, and cannabis misuse has decreased, new data suggested. A prospective cohort study of 1428 adults indicated that the mean proportion of days using cannabis increased by 0.35% annually and by 1.75% over 5 years. Cannabis misuse decreased annually (β = −0.08) and over 5 years (β = −0.4). Prelegalization use frequency influenced the use and misuse of cannabis after legalization.

2 days ago | medscape.com | Maurie Markman

This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman, from City of Hope. I'd like to present a very interesting analysis. I think it’s open to interpretation, and follow up of what I'm going to discuss is necessary, but I think it makes a number of important points relative to the question of optimal utilization o f multi-panel molecular testing as we move forward in this very exciting world of targeted therapy.

2 days ago | medscape.com | Becky McCall

AMSTERDAM — Norucholic acid (NCA), an investigational therapy, demonstrated significant superiority over placebo in halting disease progression in patients with primary sclerosing cholangitis (PSC), meeting the primary efficacy endpoint in a phase 3 trial presented on May 10 at the European Association for the Study of the Liver (EASL) Congress 2025.